INJECT: Investigation of JETREA® in patients with confirmed vitreo-macular traction

Study identification

• EU PAS number:
  EUPAS4554
• Study ID:
  23678
• Official title and acronym:
  INJECT: Investigation of JETREA® in patients with confirmed vitreo-macular traction
• DARWIN EU® study:
  No
• Study countries:
  Canada

  Germany

  Netherlands

  Norway

  Portugal

  Spain

  United Kingdom
• Study description:
  The purpose of this study is to evaluate safety, clinical effectiveness, and health-related quality of life outcomes in a real world setting among a large population of patients exposed to ocriplasmin (JETREA®) across different countries according to each country's approved indications.
• Study status:
  Finalised

Research institutions and networks

Institutions

Novartis Pharmaceuticals

Study timelines

Date when funding contract was signed

Actual:12/06/2013

Study start date

Planned:31/01/2014

Actual:24/01/2014

Date of interim report, if expected

Planned:31/07/2014

Actual:09/10/2014

Date of final study report

Planned:02/02/2017

Actual:04/12/2017

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Alcon, A Novartis Division

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable

Other study registration identification numbers and links

M-13-046